The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for patients with DLBCL.
Recently, off-the-shelf bispecific antibodies have grown in popularity; these antibodies target CD20 and a second receptor that targets CD3, which is found on vector T cells. Bispecific antibodies, as opposed to traditional monoclonal antibodies, which are monospecific, bind two epitopes simultaneously, either on the same antigen or on two different antigens. Although clinical development of these products has f...
